PepTalk 2017
PepTalk 2017
Pipeline One Header

Cambridge Healthtech Institute’s Second Annual
Emerging Technologies for Antibody Discovery
Cutting-Edge Technologies to Enable the Discovery of Novel
Biotherapeutic Targets for Antibodies and Emerging Constructs

January 12-13, 2017 | Hilton San Diego Bayfront | San Diego, CA

As large pharma continues its integration of biologic drugs into its product portfolios and discovery operations, it is imperative that industry companies identify truly novel drug targets for unmet medical needs. The Emerging Technologies for Antibody Discovery meeting offers a forum for showcasing the current state of the art for research methodologies that will support the discovery of next-generation biotherapeutics. The meeting explores the evolution of traditional library and display approaches, along with emerging technologies with the potential to have significant near-term impacts on the ability of scientists to discover and develop unique, differentiated biologic drugs.

Preliminary Agenda


KEYNOTE PRESENTATION: Increasing the Content of High-Content Assays: Targeting Diseases & Characterizing Compounds via Cell Painting

Anne Carpenter, Ph.D., Director, Imaging Platform, Broad Institute

Plug-and-(Dis)play Mammalian Cells for Protein Expression and Engineering

Sai Reddy, Ph.D., Assistant Professor, Biosystems Science and Engineering, ETH Zurich, Switzerland

Optimized Antigen Expression and Automated Antibody-Phage Display Pipeline for the Generation of Antibody Reagents to Cancer Related Surface Proteins

Michael Hornsby, Ph.D., Researcher, Pharmaceutical Chemistry, University of California, San Francisco

WebPhage: An Informatics Platform to Facilitate Biotherapeutic Discovery and Engineering

Steve Comeau, Ph.D., Bioinformatics Architect, Research & Non-Clinical Development Informatics, Shire


T-Cell Antigen Profiling by Deep Sequencing

Robert Holt, Ph.D., Head, Sequencing, Michael Smith Genome Sciences Center, BC Cancer Agency, Canada

Natively Paired B- and T-Cell Immune Repertoires and the Discovery of Potent Antibody Therapeutics

Sean Carroll, Ph.D., Scientist, Atreca

Immunosequencing for the Identification of TCRs for Adoptive T-Cell Therapy

Catherine Sanders, Ph.D., Director, Scientific Liaisons, Adaptive Biotechnologies

Applying Sequencing Technology Combinations for Human Serum mAb Discovery

Gregory C. Ippolito, Ph.D., Research Assistant Professor, Molecular Biosciences, The University of Texas at Austin

B-Cell High-Throughput Screening for CAR-T Discovery

Adrian Briggs, Head, Technology Development, Receptor Discovery, Juno Therapeutics, Inc.


Application of Cryo-EM as a Tool for Antibody Discovery and Development

Claudio Ciferri, Ph.D., Scientist, Structural Biology, Genentech

Measuring Oncogene Signaling with ImmunoPET

Michael Evans, Ph.D., Assistant Professor, Radiology and Biomedical Imaging, University of California, San Francisco

Using NGS to Enhance Cell-Based Antibody Phage Panning

John Wheeler, Principal Research Scientist, Janssen BioTherapeutics

Ultra-High-Throughput Screening of Soluble, Secreted mAbs Against Intact Cancer Cells

Yongliang Fang, Researcher, Thayer School of Engineering, Dartmouth College

The HELM Editor: How to Fully Describe Even Complex Antibody Formats in Depth

Alexander Jarasch, Ph.D., Life Science Business Consultant, Quattro Research GmbH, Germany

ProImmuneIntegrating Best-in-Class in vitro and ex vivo Assays to Manage Immunogenicity Risk in Biologics

Jeremy Fry, DPhil, Director, Sales, ProImmune

For questions about the meeting, please contact:

Kent Simmons
Senior Conference Director
Cambridge Healthtech Institute
Phone: 207-869-9199

For partnering & sponsorship information, please contact:

Companies A-K
Jason Gerardi
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Fax: 781-972-5470

Companies L-Z
Carol Dinerstein
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5471
Fax: 781-972-5470